

## Prof. EREM BİLENSOY

### Personal Information

Office Phone: [+90 312 305 4369](tel:+903123054369)

Email: [eremino@hacettepe.edu.tr](mailto:eremino@hacettepe.edu.tr)

Web: <https://www.erembilensoy.com>

### International Researcher IDs

ORCID: 0000-0003-3911-6388

ScopusID: 13105248100

Yoksis Researcher ID: 51267

### Education Information

Doctorate, Hacettepe University, Eczacılık Fakültesi, Eczacılık Teknolojisi Bölümü, Turkey 1995 - 2002

Doctorate, Université Paris XI, Eczacılık Fakültesi, Farmasötik Teknoloji, France 1995 - 2002

Postgraduate, Hacettepe University, Eczacılık Fakültesi, Eczacılık Teknolojisi Bölümü, Turkey 1992 - 1995

### Foreign Languages

English, C1 Advanced

French, B2 Upper Intermediate

Dutch, A2 Elementary

### Research Areas

Pharmacology and Therapeutics, Pharmaceutics Technology, Pharmaceutical Technology, Health Sciences

### Academic Titles / Tasks

Professor, Hacettepe University, Eczacılık Fakültesi, Eczacılık Teknolojisi Bölümü, 2013 - Continues

### Academic and Administrative Experience

Head of Department, Hacettepe University, Eczacılık Fakültesi, Eczacılık Teknolojisi Bölümü, 2022 - Continues

Hacettepe Üniversitesi, Eczacılık Fakültesi, 2010 - 2013

### Advising Theses

BİLENSOY E., POLİKATYONİK AMFİFİLİK SİKLODEKSTRİN NANOPARTİKÜLLERİN ANTİKANSER İLAÇ TAŞIYICI SİSTEM OLARAK ETKİNLİK VE GÜVENLİK AÇISINDAN DEĞERLENDİRİLMESİ, Doctorate, G.VARAN(Student), 2018

BİLENSOY E., HPV-İlişkili Servikal Kanserin Tedavisine Yönelik İlaç Yüklü Nanopartikül Formülasyonlarının Printing Teknolojisi ile Hazırlanması ve Karakterizasyonu, Doctorate, C.VARAN(Student), 2017

BİLENSOY E., Antikanser ilaç dosetakselin anyonik ve katyonik polimerik nanokapsüllerle formülasyonu ve oral uygulama sonrası etkinliğinin değerlendirilmesi, Doctorate, D.DAŞKIN(Student), 2016

BİLENSOY E., Tumor specific delivery and in vitro-in vivo evaluation of paclitaxel loaded folate-conjugated amphiphilic cyclodextrin nanoparticles, Doctorate, N.ERDOĞAR(Student), 2015

BİLENSOY E., Formulation and anticancer efficacy evaluation of polymeric and cyclodextrin nanocapsules designed for oral application, Doctorate, H.ÜNAL(Student), 2014

BİLENSOY E., Meme kanseri tedavisinde paklitaksel yüklü polikasyonik ve anyonik siklodekstrin nanoküre formülasyonu ve in vitro değerlendirilmesi, Postgraduate, G.İŞİK(Student), 2013

BİLENSOY E., Beyin glioma tedavisinde dosetaksel yüklü katyonik nanopartiküllerin tasarımı ve in vitro değerlendirilmesi, Postgraduate, C.VARAN(Student), 2013

BİLENSOY E., Mesane tümörlerinin intravezikal kemoterapisi için tasarlanmış Mitomisin C yüklü katyonik nanopartiküllerin in vitro-in vivo değerlendirilmesi, Postgraduate, N.ERDOĞAR(Student), 2011

ÇALIŞ S., BİLENSOY E., Kamptotesin içeren polimerik ve oligosakkarit bazlı nanopartiküller formülasyonların geliştirilmesi ve in vitro-in vivo değerlendirilmesi, Doctorate, Y.ÇIRPANLI(Student), 2009

BİLENSOY E., Siklodekstrin kompleksi oluşturarak, ekzemestanın çözünmesinin ve in vitro geçirgenliğinin artırılması, Postgraduate, B.YAVUZ(Student), 2009

## Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Optimization and characterization of Rituximab targeted multidrug loaded cyclodextrin nanoparticles against Non-Hodgkin Lymphoma**  
Demirturk N., VARAN G., KAĞA S., Malanga M., BİLENSOY E.  
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2024 (SCI-Expanded)
- II. **Cyclodextrin polymers containing ionizable and ionic groups: A comprehensive review from classifications and synthesis methods to applications**  
Kashani E., Maghsoudi S., Rezaia H., Yarazavi M., Hajiabbas M., Benkovics G., BİLENSOY E., Lacik I., Heydari A.  
MATERIALS TODAY CHEMISTRY, 2024 (SCI-Expanded)
- III. **Open forum conference on the ICH M13A bioequivalence guideline**  
Blume H., Wedemeyer S., Seidlitz A., Beuerle G., Klein S., BİLENSOY E.  
European Journal of Pharmaceutical Sciences, vol.196, 2024 (SCI-Expanded)
- IV. **Oral docetaxel delivery with cationic polymeric core-shell nanocapsules: In vitro and in vivo evaluation**  
Daşkın D., Erdoğan N., İSKİT A. B., BİLENSOY E.  
Journal of Drug Delivery Science and Technology, vol.80, 2023 (SCI-Expanded)
- V. **Pharmacometabolomic assessment of vitamin E loaded human serum albumin nanoparticles on HepG2 cancer cell lines**  
Şenol Y., KAPLAN O., VARAN C., Demirtürk N., Öncül S., Fidan B. B., ERCAN A., BİLENSOY E., ÇELEBİER M.  
Journal of Drug Delivery Science and Technology, vol.79, 2023 (SCI-Expanded)
- VI. **Insight into oral amphiphilic cyclodextrin nanoparticles for colorectal cancer: comprehensive mathematical model of drug release kinetic studies and antitumoral efficacy in 3D spheroid colon tumors**  
ÜNAL S., VARAN G., Benito J. M., AKTAŞ Y., BİLENSOY E.  
Beilstein Journal of Organic Chemistry, vol.19, pp.139-157, 2023 (SCI-Expanded)
- VII. **Is there a niche for zinc oxide nanoparticles in future drug discovery?**  
BİLENSOY E., VARAN C.  
Expert Opinion on Drug Discovery, vol.18, no.9, pp.943-945, 2023 (SCI-Expanded)
- VIII. **Nanocarriers targeting the diseases of the pancreas**  
Demirturk N., BİLENSOY E.  
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol.170, pp.10-23, 2022 (SCI-Expanded)
- IX. **Therapeutic efficacy and gastrointestinal biodistribution of polycationic nanoparticles for oral**

**camptothecin delivery in early and late-stage colorectal tumor-bearing animal model**

Unal S., ÖZTÜRK S. C., BİLGİÇ E., Yanik H., KORKUSUZ P., AKTAŞ Y., Benito J. M., ESENDAĞLI G., BİLENSOY E.  
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol.169, pp.168-177, 2021 (SCI-Expanded)

- X. **Q-tof lc/ms-based untargeted metabolomics approach to evaluate the effect of folate-conjugated cyclodextrins on triple-negative breast cancer cells**  
Varol I., KAPLAN O., Erdoğan N., Öncül S., Nielsen T. T., ERCAN A., BİLENSOY E., ÇELEBİER M.  
Current Pharmaceutical Analysis, vol.17, no.10, pp.1272-1281, 2021 (SCI-Expanded)
- XI. **A Review on Cancer Immunotherapy and Applications of Nanotechnology to Chemoimmunotherapy of Different Cancers**  
Akkin S., VARAN G., BİLENSOY E.  
MOLECULES, vol.26, no.11, 2021 (SCI-Expanded)
- XII. **Development of oral aprepitant-loaded chitosan-polyethylene glycol-coated cyclodextrin nanocapsules: formulation, characterization, and pharmacokinetic evaluation**  
Erdoglar N., Akkin S., Nielsen T. T., Ozcebebi E., Erdogdu B., NEMUTLU E., Iskit A. B., BİLENSOY E.  
JOURNAL OF PHARMACEUTICAL INVESTIGATION, vol.51, no.3, pp.297-310, 2021 (SCI-Expanded)
- XIII. **Polycationic cyclodextrin nanoparticles induce apoptosis and affect antitumoral activity in HepG2 cell line: An evaluation at the molecular level**  
ERCAN A., ÇELEBİER M., ÖNCÜL S., VARAN G., KOÇAK E., Benito J. M., BİLENSOY E.  
International Journal of Pharmaceutics, vol.598, 2021 (SCI-Expanded)
- XIV. **Erlotinib entrapped in cholesterol-depleting cyclodextrin nanoparticles shows improved antitumoral efficacy in 3D spheroid tumors of the lung and the liver**  
Varan G., Demirturk N., Benito J. M., BİLENSOY E.  
Journal of Drug Targeting, vol.29, no.4, pp.439-453, 2021 (SCI-Expanded)
- XV. **Determination and validation of aprepitant in rat plasma using LC-MS/MS.**  
Erdoglar N., REÇBER T., B Iskit A. B., BİLENSOY E., KIR S., NEMUTLU E.  
Bioanalysis, vol.13, no.5, pp.363-372, 2021 (SCI-Expanded)
- XVI. **Therapeutic efficacy and biodistribution of paclitaxel-bound amphiphilic cyclodextrin nanoparticles: Analyses in 3D tumor culture and tumor-bearing animals in vivo**  
Varan G., Varan C., Öztürk S. C., Benito J. M., Esendağlı G., Bilensoy E.  
Nanomaterials, vol.11, no.2, pp.1-18, 2021 (SCI-Expanded)
- XVII. **ACPA decreases non-small cell lung cancer line growth through Akt/PI3K and JNK pathways in vitro.**  
Boyacioglu O., BİLGİÇ E., VARAN C., BİLENSOY E., NEMUTLU E., GÜLMEZ SEVİM D., Kocaefe C., KORKUSUZ P.  
Cell death & disease, vol.12, no.1, pp.56, 2021 (SCI-Expanded)
- XVIII. **Erlotinib complexation with randomly methylated beta-cyclodextrin improves drug solubility, intestinal permeability, and therapeutic efficacy in non-small cell lung cancer**  
Erdoglar N., Akkin S., VARAN G., BİLENSOY E.  
PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, vol.26, pp.797-806, 2021 (SCI-Expanded)
- XIX. **Preparation and characterization of cyclodextrin nanosponges for organic toxic molecule removal**  
VARAN C., Anceschi A., Sevlı S., Bruni N., Giraudı L., BİLGİÇ E., KORKUSUZ P., Iskit A. B., Trotta F., BİLENSOY E.  
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol.585, 2020 (SCI-Expanded)
- XX. **Cyclodextrin nanoparticle bound oral camptothecin for colorectal cancer: Formulation development and optimization**  
ÜNAL S., AKTAŞ Y., Benito J. M., BİLENSOY E.  
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol.584, 2020 (SCI-Expanded)
- XXI. **Improved oral bioavailability of anticancer drug tamoxifen through complexation with water soluble cyclodextrins: in vitro and in vivo evaluation**  
Erdoğan N., NEMUTLU E., İSKİT A. B., KARA Ş. A., Teksin Z. Ş., BİLENSOY E.  
JOURNAL OF INCLUSION PHENOMENA AND MACROCYCLIC CHEMISTRY, vol.96, no.1-2, pp.81-91, 2020 (SCI-Expanded)
- XXII. **Mechanical characterization and ex vivo evaluation of anticancer and antiviral drug printed bioadhesive film for the treatment of cervical cancer**

- Varan C., Şen M., Sandler N., Aktaş Y., Bilensoy E.  
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol.130, pp.114-123, 2019 (SCI-Expanded)
- XXIII. **Plant-Based Natural Polymeric Nanoparticles as Promising Carriers for Anticancer Therapeutics**  
Varan G., VARAN C., BİLENSOY E.  
POLYMERIC NANOPARTICLES AS A PROMISING TOOL FOR ANTI-CANCER THERAPEUTICS, pp.293-318, 2019 (SCI-Expanded)
- XXIV. **Cyclodextrin-Based Nanosystems: Current Status and Future Prospects**  
VARAN C., Varan G., Erdogan N., BİLENSOY E.  
DRUG DELIVERY NANOSYSTEMS: FROM BIOINSPIRATION AND BIOMIMETICS TO CLINICAL APPLICATIONS, pp.29-58, 2019 (SCI-Expanded)
- XXV. **Global omics strategies to investigate the effect of cyclodextrin nanoparticles on MCF-7 breast cancer cells**  
ERCAN A., ÇELEBİER M., VARAN G., ÖNCÜL S., Nenni M., KAPLAN O., BİLENSOY E.  
European Journal of Pharmaceutical Sciences, vol.123, pp.377-386, 2018 (SCI-Expanded)
- XXVI. **Cellular interaction and tumoral penetration properties of cyclodextrin nanoparticles on 3D breast tumor model**  
Varan G., Patrulea V., Borchard G., BİLENSOY E.  
Nanomaterials, vol.8, no.2, 2018 (SCI-Expanded)
- XXVII. **Cyclodextrin-based polymeric nanosystems**  
Erdoglar N., Varan G., VARAN C., BİLENSOY E.  
DRUG TARGETING AND STIMULI SENSITIVE DRUG DELIVERY SYSTEMS, pp.715-748, 2018 (SCI-Expanded)
- XXVIII. **Therapeutic efficacy of folate receptor-targeted amphiphilic cyclodextrin nanoparticles as a novel vehicle for paclitaxel delivery in breast cancer**  
ERDOĞAR N., ESENDAĞLI G., Nielsen T. T., Esendagli-Yilmaz G., Yoyen-Ermis D., Erdogdu B., SARGON M. F., EROĞLU H., BİLENSOY E.  
JOURNAL OF DRUG TARGETING, vol.26, no.1, pp.66-74, 2018 (SCI-Expanded)
- XXIX. **Cyclodextrin-Based Nanosystems in Targeted Cancer Therapy**  
Erdoglar N., BİLENSOY E.  
CYCLODEXTRIN APPLICATIONS IN MEDICINE, FOOD, ENVIRONMENT AND LIQUID CRYSTALS, vol.17, pp.59-80, 2018 (SCI-Expanded)
- XXX. **Amphiphilic cyclodextrin nanoparticles**  
VARAN G., VARAN C., ERDOĞAR N., Hincal A. A., BİLENSOY E.  
International Journal of Pharmaceutics, vol.531, no.2, pp.457-469, 2017 (SCI-Expanded)
- XXXI. **Inkjet printing of antiviral PCL nanoparticles and anticancer cyclodextrin inclusion complexes on bioadhesive film for cervical administration**  
VARAN C., WICKSTRÖM H., SANDLER N., AKTAŞ Y., BİLENSOY E.  
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol.531, no.2, pp.701-713, 2017 (SCI-Expanded)
- XXXII. **Cationic PEGylated polycaprolactone nanoparticles carrying post-operation docetaxel for glioma treatment**  
VARAN C., BİLENSOY E.  
BEILSTEIN JOURNAL OF NANOTECHNOLOGY, vol.8, pp.1446-1456, 2017 (SCI-Expanded)
- XXXIII. **Amphiphilic cyclodextrin derivatives for targeted drug delivery to tumors**  
ERDOĞAR N., VARAN G., BİLENSOY E.  
Current Topics in Medicinal Chemistry, vol.17, no.13, pp.1521-1528, 2017 (SCI-Expanded)
- XXXIV. **Localized delivery of methylprednisolone sodium succinate with polymeric nanoparticles in experimental injured spinal cord model**  
KARABEY-AKYUREK Y., GURCAY A. G., GURCAN O., TURKOGLU O. F., Yabanoglu-Ciftci S., EROĞLU H., SARGON M. F., BİLENSOY E., ÖNER L.  
PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, vol.22, no.8, pp.972-981, 2017 (SCI-Expanded)
- XXXV. **Development of polycationic amphiphilic cyclodextrin nanoparticles for anticancer drug delivery**  
Varan G., Benito J. M., Mellet C. O., BİLENSOY E.

- Beilstein Journal of Nanotechnology, vol.8, no.1, pp.1457-1468, 2017 (SCI-Expanded)
- XXXVI. **An Improved and Validated HPLC Method for the Determination of Methylprednisolone Sodium Succinate and its Degradation Products in Nanoparticles**  
KARABEY-AKYUREK Y., NEMUTLU E., BİLENSOY E., ÖNER L.  
CURRENT PHARMACEUTICAL ANALYSIS, vol.13, no.2, pp.162-168, 2017 (SCI-Expanded)
- XXXVII. **Cholesterol-Targeted Anticancer and Apoptotic Effects of Anionic and Polycationic Amphiphilic Cyclodextrin Nanoparticles**  
VARAN G., ÖNCÜL S., ERCAN A., BENITO J. M., MELLET C. O., BİLENSOY E.  
Journal of Pharmaceutical Sciences, vol.105, no.10, pp.3172-3182, 2016 (SCI-Expanded)
- XXXVIII. **Design and optimization of novel paclitaxel-loaded folate-conjugated amphiphilic cyclodextrin nanoparticles**  
ERDOĞAR N., ESENDAĞLI G., Nielsen T. T., ŞEN M., ÖNER L., BİLENSOY E.  
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol.509, pp.375-390, 2016 (SCI-Expanded)
- XXXIX. **Antitumor Efficacy of Bacillus Calmette-Guerin Loaded Cationic Nanoparticles for Intravesical Immunotherapy of Bladder Tumor Induced Rat Model**  
ERDOĞAR N., İSKİT A. B., EROĞLU H., SARGON M. F., Mungan N. A., BİLENSOY E.  
JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY, vol.15, no.12, pp.10156-10164, 2015 (SCI-Expanded)
- XL. **Amphiphilic cyclodextrins as enabling excipients for drug delivery and for decades of scientific collaboration: Tribute to a distinguished scientist, French representative and friend - A historical perspective**  
AKTAŞ Y., Yenice I., BİLENSOY E., HINCAL A. A.  
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol.30, pp.261-265, 2015 (SCI-Expanded)
- XLI. **Formulation development, stability and anticancer efficacy of core-shell cyclodextrin nanocapsules for oral chemotherapy with camptothecin**  
UNAL H., Ozturk N., BİLENSOY E.  
Beilstein Journal of Organic Chemistry, vol.11, pp.204-212, 2015 (SCI-Expanded)
- XLII. **Core-shell hybrid nanocapsules for oral delivery of camptothecin: formulation development, in vitro and in vivo evaluation**  
UNAL H., D'ANGELO I., PAGANO E., BORRELLI F., IZZO A., UNGARO F., QUAGLIA F., BİLENSOY E.  
JOURNAL OF NANOPARTICLE RESEARCH, vol.17, no.1, 2015 (SCI-Expanded)
- XLIII. **Cationic polymer nanoparticles for drug and gene delivery**  
BİLENSOY E., Işık G., VARAN C.  
RSC Polymer Chemistry Series, no.13, pp.268-295, 2015 (SCI-Expanded)
- XLIV. **Amphiphilic Cyclodextrin Nanoparticles for Effective and Safe Delivery of Anticancer Drugs**  
Bilensoy E.  
GENEDIS 2014: NEURODEGENERATION, vol.822, pp.201, 2015 (SCI-Expanded)
- XLV. **Binary, ternary and microencapsulated celecoxib complexes with beta-cyclodextrin formulated via hydrophilic polymers**  
Vranic E., Grizic D., Planinsek O., Srcic S., BİLENSOY E.  
JOURNAL OF INCLUSION PHENOMENA AND MACROCYCLIC CHEMISTRY, vol.80, pp.139-146, 2014 (SCI-Expanded)
- XLVI. **Development of implantable hydroxypropyl-beta-cyclodextrin coated polycaprolactone nanoparticles for the controlled delivery of docetaxel to solid tumors**  
VARAN C., BİLENSOY E.  
JOURNAL OF INCLUSION PHENOMENA AND MACROCYCLIC CHEMISTRY, vol.80, pp.9-15, 2014 (SCI-Expanded)
- XLVII. **Cationic core-shell nanoparticles for intravesical chemotherapy in tumor-induced rat model: Safety and efficacy**  
ERDOĞAR N., İSKİT A. B., EROĞLU H., SARGON M. F., Mungan N. A., BİLENSOY E.  
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol.471, pp.1-9, 2014 (SCI-Expanded)
- XLVIII. **Wound healing activity of the Bellis perennis L. (common daisy)**  
Karakas F. P., Karakas A., Boran C., Turker A. U., YALÇIN F. N., BİLENSOY E.  
NEW BIOTECHNOLOGY, vol.29, 2012 (SCI-Expanded)

- XLIX. **Prolonged retention and in vivo evaluation of cationic nanoparticles loaded with Mitomycin C designed for intravesical chemotherapy of bladder tumours**  
Erdogar N., İSKİT A. B., Mungan N. A., BİLENSOY E.  
Journal of Microencapsulation, vol.29, no.6, pp.576-582, 2012 (SCI-Expanded)
- L. **The evaluation of topical administration of Bellis perennis fraction on circular excision wound healing in Wistar albino rats**  
Karakaş F. P., Karakaş A., Boran Ç., Türker A. U., YALÇIN F. N., BİLENSOY E.  
Pharmaceutical Biology, vol.50, no.8, pp.1031-1037, 2012 (SCI-Expanded)
- LI. **Rapamycin-cyclodextrin complexation: Improved solubility and dissolution rate**  
Abdur Rouf M., VURAL İ., BİLENSOY E., Hincal A., Erol D. D.  
Journal of Inclusion Phenomena and Macrocyclic Chemistry, vol.70, pp.167-175, 2011 (SCI-Expanded)
- LII. **Preface**  
BİLENSOY E.  
Cyclodextrins in Pharmaceutics, Cosmetics, and Biomedicine: Current and Future Industrial Applications, 2011 (SCI-Expanded)
- LIII. **Antitumoral activity of camptothecin-loaded nanoparticles in 9L rat glioma model**  
Çirpanlı Y., Allard E., Passirani C., Bilensoy E., Lemaire L., Çalış S., Benoit J.  
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol.403, pp.201-206, 2011 (SCI-Expanded)
- LIV. **A double-blind placebo-controlled study of 5-fluorouracil: Cyclodextrin complex loaded thermosensitive gel for the treatment of HPV induced condyloma**  
BİLENSOY E., Moroy P., Çirpanlı Y., Bilensoy T., ÇALIŞ S., Mollamahmutoglu L.  
Journal of Inclusion Phenomena and Macrocyclic Chemistry, vol.69, pp.309-313, 2011 (SCI-Expanded)
- LV. **Comparative evaluation of in vitro parameters of tamoxifen citrate loaded poly(lactide-co-glycolide), poly( $\epsilon$ -caprolactone) and chitosan nanoparticles**  
Çirpanlı Y., Yerlikaya F., Ozturk K., Erdogar N., Launay M., Gegu C., Leturgez T., BİLENSOY E., ÇALIŞ S., ÇAPAN Y.  
Pharmazie, vol.65, no.12, pp.867-870, 2010 (SCI-Expanded)
- LVI. **Preparation and characterization of cationic nanoparticles loaded with Mitomycin C by double emulsion and ionotropic gelation techniques.**  
Erdoğar N., Mungan A., Bilensoy E.  
Journal of controlled release : official journal of the Controlled Release Society, vol.148, no.1, 2010 (SCI-Expanded)
- LVII. **An alternative cyclodextrin based formulation for oral anticancer drug exemestane: In vitro and cell culture studies.**  
Yavuz B., Sarisözen C., Vural İ., Bilensoy E., Sumnu M.  
Journal of controlled release : official journal of the Controlled Release Society, vol.148, no.1, 2010 (SCI-Expanded)
- LVIII. **Alternative oral exemestane formulation: Improved dissolution and permeation**  
Yavuz B., BİLENSOY E., VURAL İ., Sumnu M.  
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol.398, pp.137-145, 2010 (SCI-Expanded)
- LIX. **Cationic nanoparticles for cancer therapy**  
BİLENSOY E.  
Expert Opinion on Drug Delivery, vol.7, no.7, pp.795-809, 2010 (SCI-Expanded)
- LX. **Development of polymeric and cyclodextrin nanoparticles for camptothecin delivery.**  
Çirpanlı Y., Bilensoy E., Dogan A. L., Calis S.  
Journal of controlled release : official journal of the Controlled Release Society, vol.148, no.1, 2010 (SCI-Expanded)
- LXI. **Antibacterial activity of triclosan chitosan coated graft on hernia graft infection model**  
Çakmak A., Çirpanlı Y., Bilensoy E., Yorgancı K., Çalış S., Saribaş Z., Kaynaroğlu V.  
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol.381, no.2, pp.214-219, 2009 (SCI-Expanded)
- LXII. **Recent advances and future directions in amphiphilic cyclodextrin nanoparticles**  
BİLENSOY E., Hincal A. A.  
Expert Opinion on Drug Delivery, vol.6, no.11, pp.1161-1173, 2009 (SCI-Expanded)
- LXIII. **ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF TAMOXIFEN CITRATE USING NORMAL PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY**

- Yerlikaya F., Launay M., Gegu C., Leturgez T., BİLENSOY E., ÇALIŞ S., ÇAPAN Y.  
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol.38, no.1, pp.183-184, 2009 (SCI-Expanded)
- LXIV. **Comparative evaluation of polymeric and amphiphilic cyclodextrin nanoparticles for effective camptothecin delivery**  
Çirpanlı Y., Bilensoy E., Lale Doğan A., Çalış S.  
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol.73, no.1, pp.82-89, 2009 (SCI-Expanded)
- LXV. **Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of Mitomycin C to bladder tumors**  
Bilensoy E., Sarisozen C., Esendagli G., Doğan A., Aktas Y., Şen M., Mungan N. A.  
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol.371, pp.170-176, 2009 (SCI-Expanded)
- LXVI. **Nanoparticulate delivery systems based on amphiphilic cyclodextrins**  
BİLENSOY E.  
Journal of Biomedical Nanotechnology, vol.4, no.3, pp.293-303, 2008 (SCI-Expanded)
- LXVII. **Hyaluronic acid coated poly-ε-caprolactone nanospheres deliver high concentrations of cyclosporine A into the cornea**  
Yenice I., Mocan M. C., PALASKA E., Bochot A., BİLENSOY E., VURAL İ., Irkeç M., Atilla Hincal A.  
Experimental Eye Research, vol.87, no.3, pp.162-167, 2008 (SCI-Expanded)
- LXVIII. **Development of nonsurfactant cyclodextrin nanoparticles loaded with anticancer drug paclitaxel**  
Bilensoy E., Gurkaynak O., Ertan M., Şen M., Hincal A. A.  
JOURNAL OF PHARMACEUTICAL SCIENCES, vol.97, pp.1519-1529, 2008 (SCI-Expanded)
- LXIX. **Safety and efficacy of amphiphilic β-cyclodextrin nanoparticles for paclitaxel delivery**  
BİLENSOY E., Gürkaynak O., DOĞAN A., Hincal A. A.  
International Journal of Pharmaceutics, vol.347, pp.163-170, 2008 (SCI-Expanded)
- LXX. **Thermosensitive mucoadhesive gel formulation loaded with 5-Fu: cyclodextrin complex for HPV-induced cervical cancer**  
Bilensoy E., Cirpanlı Y., Sen M., Dogan A. L., Calis S.  
JOURNAL OF INCLUSION PHENOMENA AND MACROCYCLIC CHEMISTRY, vol.57, pp.363-370, 2007 (SCI-Expanded)
- LXXI. **Complexation behavior of antiestrogen drug tamoxifen citrate with natural and modified beta-cyclodextrins**  
Bilensoy E., Dogan L., Sen M., Hincal A.  
JOURNAL OF INCLUSION PHENOMENA AND MACROCYCLIC CHEMISTRY, vol.57, pp.651-655, 2007 (SCI-Expanded)
- LXXII. **Cytotoxic evaluation of injectable cyclodextrin nanoparticles**  
Memisoglu-Bilensoy E., DOĞAN A., Hincal A. A.  
Journal of Pharmacy and Pharmacology, vol.58, no.5, pp.585-589, 2006 (SCI-Expanded)
- LXXIII. **Mucoadhesive, thermosensitive, prolonged-release vaginal gel for clotrimazole: β-cyclodextrin complex**  
Bilensoy E., Rouf M. A., Vural İ., Sen M., Hincal A. A.  
AAPS PharmSciTech, vol.7, no.2, 2006 (SCI-Expanded)
- LXXIV. **Sterile, injectable cyclodextrin nanoparticles: Effects of gamma irradiation and autoclaving**  
Memisoglu-Bilensoy E., Hincal A. A.  
International Journal of Pharmaceutics, vol.311, pp.203-208, 2006 (SCI-Expanded)
- LXXV. **Effect of drug physicochemical properties on in vitro characteristics of amphiphilic cyclodextrin nanospheres and nanocapsules**  
Memisoglu-Bilensoy E., Sen M., Hincal A. A.  
Journal of Microencapsulation, vol.23, no.1, pp.59-68, 2006 (SCI-Expanded)
- LXXVI. **Thermosensitive vaginal gel formulation for the controlled release of clotrimazole via complexation to beta-cyclodextrin.**  
BİLENSOY E., Rouf M., VURAL İ., Hincal A.  
Journal of controlled release : official journal of the Controlled Release Society, vol.116, no.2, 2006 (SCI-Expanded)
- LXXVII. **Tamoxifen citrate loaded amphiphilic β-cyclodextrin nanoparticles: In vitro characterization and**

### **cytotoxicity**

Memisoglu-Bilensoy E., VURAL İ., Bochet A., Renoir J. M., Duchene D., Hincal A. A.  
Journal of Controlled Release, vol.104, no.3, pp.489-496, 2005 (SCI-Expanded)

### **LXXVIII. Tamoxifen citrate loaded amphiphilic $\beta$ -cyclodextrin nanoparticles: System development and evaluation**

Memisoglu-Bilensoy E.

European Journal of Pharmaceutical Sciences, vol.25, 2005 (SCI-Expanded)

### **LXXIX. Transcription efficiency of tamoxifen citrate-loaded $\beta$ -cyclodextrin nanoparticles**

VURAL İ., Memisoglu-Bilensoy E., Renoir J., Bochet A., Duchêne D., Hincal A.

Journal of Drug Delivery Science and Technology, vol.15, no.5, pp.339-342, 2005 (SCI-Expanded)

## **Articles Published in Other Journals**

- I. **Printers and Printing Technologies in the Pharmaceutical Field Yazıcılar ve Baskı Teknolojilerinin Farmasötik Alanda Kullanımı**  
Çobanoğlu E., VARAN C., BİLENSOY E.  
Fabad Journal of Pharmaceutical Sciences, vol.46, no.1, pp.43-78, 2021 (Scopus)
- II. **The effect of Quercus coccifera L. Extract on the Necrosis of Random-pattern Skin Flaps in Rats Quercus coccifera L. Ekstresinin Random Patern Deri Flebi Nekrozu Üzerine Etkisi**  
Orhan E., Aka İ. Ö., Yüzbaşıoğlu M., Yavuz B., BİLENSOY E., Uz A.  
Haseki Tip Bulteni, vol.57, no.3, pp.249-254, 2019 (Scopus)
- III. **The effect of Arnebia purpurea extract on the survival of random pattern skin flaps in rats**  
ORHAN A. E., YÜZBAŞIOĞLU M., EROL Y. R., BİLENSOY E., ERDOĞAR N., DEMİREZER L. Ö., UZ A.  
The European Research Journal, vol.4, pp.152-156, 2018 (Peer-Reviewed Journal)
- IV. **Nanocapsules for drug delivery: An updated review of the last decade**  
Erdoğan N., Akkin S., BİLENSOY E.  
Recent Patents on Drug Delivery and Formulation, vol.12, no.4, pp.252-266, 2018 (Scopus)
- V. **Siklodekstrinler ve Biyomedikal Alandaki Uygulamaları**  
ÇELEN N., BİLENSOY E., ÇALIŞ S.  
Hacettepe University Journal of the Faculty Pharmacy, 2016 (Peer-Reviewed Journal)
- VI. **Cyclodextrins and their applications in biomedical field Siklodekstrinler ve Biyomedikal Alandaki Uygulamaları**  
Çelen N., BİLENSOY E., ÇALIŞ S.  
Hacettepe University Journal of the Faculty of Pharmacy, vol.36, no.1, pp.50-69, 2016 (Scopus)
- VII. **Role of Nanoparticles in the Treatment of Noninvasive Bladder Cancer**  
BİLENSOY E., Erdogar N., Mungan A. N.  
UROONKOLOJİ BULTENİ-BULLETIN OF UROONCOLOGY, vol.14, no.1, pp.61-66, 2015 (ESCI)
- VIII. **Bioavailability File: Exemestane**  
YAVUZ B., BİLENSOY E., Sumnu M.  
FABAD J. Pharm. Sci., vol.32, no.2, pp.79-89, 2007 (Peer-Reviewed Journal)
- IX. **Analytical Method Validation for HPLC Assay of Oral Anticancer Drug Exemestane**  
YAVUZ B., BİLENSOY E., Sumnu M.  
FABAD J. Pharm. Sci., vol.32, no.1, pp.15-22, 2007 (Peer-Reviewed Journal)

## **Books & Book Chapters**

### **I. Biodistribution of polymeric, polysaccharide and metallic nanoparticles**

Erdoğan N., Varan G., Varan C., Bilensoy E.

in: Characterization of Pharmaceutical Nano- and Microsystems, Peltonen Leena, Douroumis Dennis, Fahr



Alfred, Siepmann Jürgen, Snowden Martin J., Editor, John Wiley & Sons, West Sussex, UK, Cambridge, pp.275-290, 2020

**II. Cyclodextrin Based Nano-Systems: Current Status and Future Prospects**

VARAN C., VARAN G., ERDOĞAR N., BİLENSOY E.

in: Drug Delivery Nanosystems: From Bioinspiration and Biomimetics to Clinical Applications, Pippa Natassa, Demetzos Costas, Pispas Stergios, Editor, Pan Stanford, pp.29-49, 2019

**III. Plant based natural polymer (Guar gum, pectin, starch, cellulose, cyclodextrins) nanoparticles as promising tool for anticancer therapeutics**

VARAN G., VARAN C., BİLENSOY E.

in: Polymeric Nanoparticles as a Promising Tool for Anti-cancer Therapeutics, Prashant Kesharwani, Kishore M. Paknikar, Virendra Gajbhiye, Editor, Academic Press, 2019

**IV. Cyclodextrin-based polymeric nanosystems**

ERDOĞAR N., VARAN G., VARAN C., BİLENSOY E.

in: Drug Targeting and Stimuli Sensitive Drug Delivery Systems, Alina M. Holban, Editor, William Andrew, pp.715-748, 2018

**V. Cyclodextrin-Based Nanosystems in Targeted Cancer Therapy**

ERDOĞAR N., BİLENSOY E.

in: Cyclodextrin Applications in Medicine, Food, Environment and Liquid Crystals, Gregorio Crini, Eric Lichtfouse, Sophie Fourmentin, Editor, Springer, Cham, pp.59-80, 2018

**VI. Cationic polymer nanoparticles for drug and gene delivery**

BİLENSOY E., İŞİK G., VARAN C.

in: Cationic Polymers in Regenerative Medicine, Samal Sangram K., Dubruel Peter, Editor, Royal Society of Chemistry, 2015

## Refereed Congress / Symposium Publications in Proceedings

**I. Development and Characterization of Erlotinib-Randomly Methylated- $\beta$ -cyclodextrin Complex for the Treatment of Non-small Lung Cancer**

ERDOĞDU N., Akkın S., VARAN G., BİLENSOY E.

13th International Symposium of Pharmaceutical Science, Ankara, Turkey, 22 - 25 June 2021

**II. Farelerde Tamoksifen ve Majör Metaboliti N-Desmetil-Tamoksifen'in LC- MS/MS Yöntemiyle Tayini**

ERDOĞAR N., NEMUTLU E., KIR S., İSKİT A. B., BİLENSOY E.

XVI. Ulusal Spektroskopik Kongresi, Turkey, 7 - 09 November 2019

**III. Development of a new antiproliferative arachidonoylcyclopropylamide (ACPA) releasing nanoparticle-based drug for endometrial cancers by targeting cannabinoid 1 receptors**

BİLGİÇ E., BOYACIOĞLU Ö., VARAN C., BİLENSOY E., NEMUTLU E., KARAOSMANOĞLU B., TAŞKIRAN Z. E., KORKUSUZ P.

EACR Conference Nanotechnology in Cancer: Engineering for Oncology, 12 - 14 September 2019

**IV. Cannabinoid Receptor 1-Mediated Antiproliferative Effect of ACPA and ACPA-PCL Controlled Release System on Non-Small Cell Lung Cancer Lines**

BOYACIOĞLU Ö., BİLGİÇ E., VARAN C., BİLENSOY E., NEMUTLU E., KARAOSMANOĞLU B., TAŞKIRAN Z. E., KORKUSUZ P.

EACR Conference Nanotechnology in Cancer: Engineering for Oncology, Cambridge, Canada, 12 - 14 September 2019

**V. A Metabolomic Study to Investigate the Effect of Folate Conjugated Nanoparticles on Triple Negative Breast Cancer Cells**

ERCAN A., ÇELEBİER M., varol ı., KAPLAN O., Varan G., ÖNCÜL S., KOÇAK E., BİLENSOY E.

EUFEPS Annual Meeting 2019 PERSONALIZED MEDICINES, TARGETED THERAPIES, PRECISION DRUG DELIVERY, 6 - 08 March 2019

**VI. Development and Characterization of Arachidonoylcyclopropylamide-Loaded Polycaprolactone**

## **Nanoparticle Drug Formulation**

BOYACIOĞLU Ö., BİLGİÇ E., VARAN C., BİLENSOY E., NEMUTLU E., KORKUSUZ P.

24th International Biomedical Science Technology Symposium, 17 - 20 October 2019

- VII. **The effect of polycationic amphiphilic cyclodextrin nanoparticles on mda-mb cancer cells: A metabolomic approach to understand the mechanism**  
ÇELEBİER M., KAPLAN O., VARAN G., ÖNCÜL S., KOÇAK E., ERCAN A., BİLENSOY E.  
12 th International symposium on pharmaceutical sciences, 26 June 2018
- VIII. **Mechanical Characterization and ex vivo Evaluation of Inkjet Printed Bioadhesive Film Formulation of Complexed Paclitaxel and Nanoparticulate Cidofovir**  
VARAN C., ŞEN M., SANDLER N., AKTAŞ Y., BİLENSOY E.  
EUFEPS Annual Meeting 2018, Atina, Greece, 24 - 26 May 2018
- IX. **GENOMIC AND METABOLOMIC STUDIES OF POLYCATIONIC AMPHIPHILIC CYCLODEXTRIN NANOPARTICLES ON HEPG2 CELL LINE**  
ERCAN A., ÇELEBİER M., Varan G., ÖNCÜL S., KOÇAK E., KAPLAN O., BİLENSOY E.  
EUFEPS Annual Meeting 2018 Crossing Barriers for Future Medicines, 24 - 26 May 2018
- X. **Printing and characterization of antiviral and anticancer drug loaded film formulation by using inkjet printer**  
VARAN C., ŞEN M., SANDLER N., AKTAŞ Y., BİLENSOY E.  
7th BBBB International Conference on Pharmaceutical Sciences, 5 - 07 October 2017
- XI. **Anticancer and Antiviral Drug Printed Bioadhesive Film for Cervical Cancer: Ink Formulation Development by using Cyclodextrin Derivatives**  
VARAN C., SANDLER N., BİLENSOY E.  
5th European Cyclodextrin Conference, 3 - 06 October 2017
- XII. **Preparation and Characterization of Antiviral and Anticancer Drug Printed Film Formulations for the treatment of Cervical Cancer**  
VARAN C., ŞEN M., SANDLER N., BİLENSOY E.  
SANKO University Innovation in Medicine Summit, 11 - 13 May 2017
- XIII. **Evaluation of Cholesterol-Targeted Amphiphilic Cyclodextrin Nanoparticles for Cancer Therapy**  
VARAN G., ÖNCÜL S., ERCAN A., BENÍTO J., MELLET C. O., BİLENSOY E.  
Innovation in Medicine Meetings III Congress, 11 - 13 May 2017
- XIV. **Novel Folate-Conjugated Amphiphilic Cyclodextrin Nanoparticles For Paclitaxel Delivery in Recurrent Metastatic Breast Cancer**  
ERDOĞAR N., ESENDAĞLI G., NIELSEN T. T., ESENDAĞLI YILMAZ G., SARGON M. F., ÖNER L., BİLENSOY E.  
Innovation in Medicine Summit-3, 11 - 13 May 2017
- XV. **Nanoparticulate Cidofovir and Paclitaxel Cyclodextrin Complex Combination in Ink Jet Printed Adhesive Film for HPV Infection**  
VARAN C., SANDLER N., BİLENSOY E.  
4th European Conference on Cyclodextrins, 6 - 09 October 2015
- XVI. **In Vitro and In Vivo Evaluation of Tumor Targeted Nanoparticles for Paclitaxel Delivery with Folate conjugated Amphiphilic Cyclodextrin Derivatives**  
ERDOĞAR N., TERNDROP N., ÖNER L., ESENDAĞLI G., BİLENSOY E.  
4th European Conference on Cyclodextrins (EUROCD 2015), 6 - 09 October 2015
- XVII. **Cefixime oral bioavailability improved by cyclodextrin inclusion complex In vitro in vivo evaluation**  
ÇELEN N., ÖZTÜRK N., BİLENSOY E., ÇALIŞ S.  
4th European Conference on Cyclodextrins, 6 - 09 October 2015
- XVIII. **Effects Of Quercus coccifera on Viability of Random Pattern Skin Flaps in Rats**  
ORHAN A. E., ÖZKAYA AKA İ., YÜZBAŞIOĞLU M., BİLENSOY E., YAVUZ B., UZ A.  
9th BAPRAS (Balkan Association of Plastic Reconstructive And Aesthetic Surgery) Congress, + Day Aesthetic Symposium Figures and Shapes in the Balkans, 17 - 20 September 2015, pp.64
- XIX. **Preparation and characterization of Cidofovir and Paclitaxel loaded bioadhesive film for the treatment of HPV induced cervical cancer by printing technology**

VARAN C., SANDLER N., AKTAŞ Y., BİLENSOY E.

EUFEPS Annual Meeting 2015, 15 - 17 June 2015

- XX. **Optimization by 32 Factorial Design of Tumor Targeted Nanoparticles for Paclitaxel Delivery with Folate conjugated Amphiphilic Cyclodextrin**  
ERDOĞAR N., ÖNER L., ESENDAĞLI G., NIELSEN T., BİLENSOY E.  
EUFEPS Annual Meeting, 15 - 17 June 2015
- XXI. **Docetaxel loaded hydroxypropyl B cyclodextrin polycaprolactone nanoparticles formulation development and in vitro characterization**  
VARAN C., BİLENSOY E.  
17th International Pharmaceutical Technology Symposium, 8 - 10 September 2014
- XXII. **Development of Docetaxel loaded Hydroxypropyl-β-Cyclodextrin Polycaprolactone Nanoparticles for The Treatment of Solid Tumors**  
VARAN C., BİLENSOY E.  
3rd European Conference on Cyclodextrins, 2 - 04 October 2013
- XXIII. **Docetaxel-loaded cationic core-shell polycaprolactone nanoparticles designed for rat glioma model**  
VARAN C., BİLENSOY E.  
9th Central European Symposium on Pharmaceutical Technology: CESPT 2012, 20 - 22 September 2012
- XXIV. **Docetaxel-loaded core-shell polycaprolactone nanoparticles: formulation development and characterization**  
VARAN C., BİLENSOY E.  
16th International Pharmaceutical Technology Symposium, 10 - 12 September 2012
- XXV. **Polycaprolactone nanoparticles for rat glioma model: influence of formulation parameters on the particle size and zeta potential**  
VARAN C., BİLENSOY E.  
8th Nanoscience and Nanotechnology Congress International Academy of Nanomedicine 3rd World Congress, 25 - 29 June 2012
- XXVI. **Core-shell polycaprolactone nanoparticles for rat glioma model: formulation development and characterization**  
VARAN C., BİLENSOY E.  
CRS Nordic Chapter Meeting, 3 - 05 June 2012
- XXVII. **Safety and Efficacy of Amphiphilic Cyclodextrins for Drug Delivery**  
Hincal A. A., EROĞLU H., BİLENSOY E.  
9th International Meeting of the International-Society-for-the-Study-of-Xenobiotics(ISSX), İstanbul, Turkey, 4 - 08 September 2010, vol.42, pp.12-13
- XXVIII. **Inclusion complexation of rapamycin with beta-cyclodextrin to improve solubility and stability of the drug**  
Rouf M. A., Bilensoy E., Vural I., Hincal A. A.  
2nd BBBB Conference on Pharmaceutical Sciences, Tartu, Estonia, 13 - 15 September 2007, vol.32
- XXIX. **Bioadhesive coated poly-epsilon-caprolactone nanoparticles loaded with Mitomycin C for the treatment of superficial bladder tumors**  
Sarisozen C., Aktas Y., Mungan A., Bilensoy E.  
2nd BBBB Conference on Pharmaceutical Sciences, Tartu, Estonia, 13 - 15 September 2007, vol.32
- XXX. **Tumor targeted nanoparticles for cancer therapy**  
Bilensoy E.  
2nd BBBB Conference on Pharmaceutical Sciences, Tartu, Estonia, 13 - 15 September 2007, vol.32
- XXXI. **Stabilization of camptothecin in PLGA nanoparticles**  
Cirpanli Y., Bilensoy E., Calis S., Hincal A. A.  
2nd BBBB Conference on Pharmaceutical Sciences, Tartu, Estonia, 13 - 15 September 2007, vol.32
- XXXII. **Determination of stability of rapamycin following exposure to different conditions**  
Rouf M. A., Bilensoy E., Vural I., Hincal A. A.  
2nd BBBB Conference on Pharmaceutical Sciences, Tartu, Estonia, 13 - 15 September 2007, vol.32

### XXXIII. Targeted nanoparticles for cancer therapy

Bilensoy E.

31st Congress of the Federation-of-European-Biochemical-Societies (FEBS), İstanbul, Turkey, 24 - 29 June 2006, vol.273, pp.35

### XXXIV. Formulation of poorly water soluble drugs with amphiphilic beta cyclodextrins

Hincal A., Bilensoy E.

18th Helsinki Drug Research, Helsinki, Finland, 1 - 02 June 2006, vol.28

## Supported Projects

KORKUSUZ P., BOYACIOĞLU Ö., BİLGİÇ E., BİLENSOY E., NEMUTLU E., VARAN C., Project Supported by Higher Education Institutions, Kontrollü ACPA salım sisteminin endometriyum kanserindeki CB1 reseptörü aracılı antiproliferatif ve apoptotik etkisinin araştırılması, 2018 - 2020

BİLENSOY E., Varan G., ESENDAĞLI G., Varan C., Project Supported by Higher Education Institutions, Paklitaksel yüklü siklodekstrin nanopartiküllerin antitümöral etkinliğinin araştırılması, 2017 - 2020

KORKUSUZ P., Boyacıoğlu Ö., BİLGİÇ E., BİLENSOY E., VARAN C., Project Supported by Higher Education Institutions, Küçük hücreli dışı akciğer adenokarsinomunda kannabinoidlerin CB reseptörleri aracılı olası antiproliferatif ve proapoptotik etkisinin araştırılması, 2018 - 2019

BİLENSOY E., Project Supported by Higher Education Institutions, BBBB Farmasötik Bilimler Konferansı, 2017 - 2018

BİLENSOY E., Project Supported by Higher Education Institutions, PSWC Farmasötik Bilimler Dünya Kongresi, 2017 - 2018

BİLENSOY E., Project Supported by Higher Education Institutions, PEG-PCL nanopartiküllerin antitümöral etkinliği üzerine çalışmalar, 2017 - 2017

BİLENSOY E., Project Supported by Higher Education Institutions, 13. Türkiye Eczacılık Kongresi, 2016 - 2017

BİLENSOY E., VARAN G., Project Supported by Higher Education Institutions, Paklitaksel yüklü polikationik siklodekstrin nanopartiküllerin kanser tedavisi için hücrel etkileşim ve tümöral penetrasyon özelliklerinin araştırılması, 2016 - 2017

ÇALIŞ S., BİLENSOY E., İSKİT A. B., ÇELEN N., Project Supported by Higher Education Institutions, Sefiksimin Düşük Çözünürlük ve Permeabilitesinin Siklodekstrin Türevi Kullanılarak Artırılması Üzerine İn Vivo Çalışmalar, 2015 - 2017

BİLENSOY E., Project Supported by Higher Education Institutions, Kompleks İlaçlarda Bilim ve Ruhsatlandırmada Gelişmeler, 2016 - 2016

BİLENSOY E., ERDOĞAR N., Project Supported by Higher Education Institutions, Paklitaksel Yüklü Folat-Konjuge Amfililik Siklodekstrin Nanopartiküllerin Tümöre Spesifik Taşınımı ve İn Vitro-İn Vivo Değerlendirilmesi, 2016 - 2016

BİLENSOY E., Project Supported by Higher Education Institutions, Nanoilaçlar ve nanobenzerler: güncel regülasyonlar ve pazar durumu, 2016 - 2016

BİLENSOY E., Project Supported by Higher Education Institutions, Siklodekstrinlerin İlaç Taşıyıcı Sistem Olarak Kullanımı, 2015 - 2016

BİLENSOY E., ABACI S., YAMAN Y. T., Project Supported by Higher Education Institutions, Tamoksifenin Biyoyararlanımın Araştırılması ve Elektrokimyasal Tayini, 2015 - 2016

BİLENSOY E., Project Supported by Higher Education Institutions, Kanser tedavisinde nanopartiküllerin in vitro ve in vivo değerlendirilmesi, 2015 - 2015

## Metrics

Publication: 144

Citation (WoS): 2025

Citation (Scopus): 2261

H-Index (WoS): 25

H-Index (Scopus): 26